» Articles » PMID: 34330900

Endo-lysosomal Aβ Concentration and PH Trigger Formation of Aβ Oligomers That Potently Induce Tau Missorting

Overview
Journal Nat Commun
Specialty Biology
Date 2021 Jul 31
PMID 34330900
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Amyloid-β peptide (Aβ) forms metastable oligomers >50 kDa, termed AβOs, that are more effective than Aβ amyloid fibrils at triggering Alzheimer's disease-related processes such as synaptic dysfunction and Tau pathology, including Tau mislocalization. In neurons, Aβ accumulates in endo-lysosomal vesicles at low pH. Here, we show that the rate of AβO assembly is accelerated 8,000-fold upon pH reduction from extracellular to endo-lysosomal pH, at the expense of amyloid fibril formation. The pH-induced promotion of AβO formation and the high endo-lysosomal Aβ concentration together enable extensive AβO formation of Aβ42 under physiological conditions. Exploiting the enhanced AβO formation of the dimeric Aβ variant dimAβ we furthermore demonstrate targeting of AβOs to dendritic spines, potent induction of Tau missorting, a key factor in tauopathies, and impaired neuronal activity. The results suggest that the endosomal/lysosomal system is a major site for the assembly of pathomechanistically relevant AβOs.

Citing Articles

The Aβ:Aβ ratio modulates aggregation in beta-amyloid oligomers and drives metabolic changes and cellular dysfunction.

Haessler A, Gier S, Jung N, Windbergs M Front Cell Neurosci. 2024; 18:1516093.

PMID: 39717390 PMC: 11664223. DOI: 10.3389/fncel.2024.1516093.


Enhanced β-Amyloid Aggregation in Living Cells Imaged with Quinolinium-Based Spontaneous Blinking Fluorophores.

Liu H, Cao Y, Deng Y, Wei L, Yan J, Xiao L Chem Biomed Imaging. 2024; 2(1):56-63.

PMID: 39473459 PMC: 11504592. DOI: 10.1021/cbmi.3c00081.


MAD-microbial (origin of) Alzheimer's disease hypothesis: from infection and the antimicrobial response to disruption of key copper-based systems.

Min J, Sarlus H, Harris R Front Neurosci. 2024; 18:1467333.

PMID: 39416952 PMC: 11480022. DOI: 10.3389/fnins.2024.1467333.


Yin-Yang: two sides of extracellular vesicles in inflammatory diseases.

Zeng B, Li Y, Khan N, Su A, Yang Y, Mi P J Nanobiotechnology. 2024; 22(1):514.

PMID: 39192300 PMC: 11351009. DOI: 10.1186/s12951-024-02779-9.


NHE1 Protein in Repetitive Mild TBI-Mediated Neuroinflammation and Neurological Function Impairment.

Bielanin J, Metwally S, Oft H, Paruchuri S, Lin L, Capuk O Antioxidants (Basel). 2024; 13(7).

PMID: 39061904 PMC: 11274226. DOI: 10.3390/antiox13070836.


References
1.
Cline E, Bicca M, Viola K, Klein W . The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. J Alzheimers Dis. 2018; 64(s1):S567-S610. PMC: 6004937. DOI: 10.3233/JAD-179941. View

2.
Kutzsche J, Jurgens D, Willuweit A, Adermann K, Fuchs C, Simons S . Safety and pharmacokinetics of the orally available antiprionic compound PRI-002: A single and multiple ascending dose phase I study. Alzheimers Dement (N Y). 2020; 6(1):e12001. PMC: 7087413. DOI: 10.1002/trc2.12001. View

3.
Walsh D, Lomakin A, Benedek G, Condron M, Teplow D . Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem. 1997; 272(35):22364-72. DOI: 10.1074/jbc.272.35.22364. View

4.
Lord A, Englund H, Soderberg L, Tucker S, Clausen F, Hillered L . Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J. 2009; 276(4):995-1006. PMC: 2752010. DOI: 10.1111/j.1742-4658.2008.06836.x. View

5.
Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G . Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody. Alzheimers Res Ther. 2016; 8(1):14. PMC: 4822297. DOI: 10.1186/s13195-016-0181-2. View